EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AAV9/SLC6A1 gene therapy rescues abnormal EEG patterns and cognitive behavioral deficiencies in Slc6a1–/– mice

Weirui Guo, Matthew Rioux, Frances Shaffo, Yuhui Hu, Ze Yu, Chao Xing, Steven J Gray

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci182235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Weirui Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Electroencephalography, GABA Plasma Membrane Transport Proteins. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Taysha Gene Therapies, SLC6A1 Connect.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The solute carrier family 6 member 1 ( SLC6A1 ) gene encodes the γ-aminobutyric acid (GABA) transporter GAT-1, the deficiency of which is associated with infantile encephalopathy with intellectual disability. We designed 2 AAV9 vectors, with either the JeT or MeP promoter, and conducted preclinical gene therapy studies using heterozygous and homozygous Slc6a1 -KO mice at different developmental ages and various routes of administration. Neonatal intracerebroventricular administration of either vector resulted in significantly normalized EEG patterns in Slc6a1 –/– or Slc6a1 +/– mice as well as improvement in several behavioral phenotypes of Slc6a1 –/– mice. However, some mortality and adverse effects were observed in neonatal-treated mice. Intrathecal administration of either vector at P5 normalized EEG patterns in Slc6a1 +/– mice, but in Slc6a1 –/– mice, the treatment only rescued nest building without impact on EEG. Both vectors were well tolerated in all mice treated at P5 or later (including WT mice), up to 1 year after injection. Overall, our data demonstrate compelling efficacy when mice are treated at an early development age. We also identified that outside of the neonatal treatment window, the severe homozygous KO model is more refractory to treatment, whereas our treatments in the heterozygous mice, which genotypically match human patients, have resulted in stronger benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusGenetic TherapyElectroencephalographyGABA Plasma Membrane Transport ProteinsAnimalsMiceMice, KnockoutGenetic VectorsMaleBehavior, Animal

Stichwörter der Autor:innen

Neurological disordersTherapeutics

Substanzen

GABA Plasma Membrane Transport Proteins

Autor:innen und Institutionen

  • Department of Pediatrics.
  • McDermott Center for Human Growth and Development.
  • Department of Bioinformatics.
  • O'Donnell School of Public Health.
  • Department of Neurology.
  • Department of Molecular Biology, and.

Förderung

  • NIDDK NIH HHS
  • Taysha Gene Therapies
  • SLC6A1 Connect

Zitieren

APA

Guo, W., Rioux, M., Shaffo, F., Hu, Y., Yu, Z., Xing, C., & Gray, S. J. (2025). AAV9/SLC6A1 gene therapy rescues abnormal EEG patterns and cognitive behavioral deficiencies in Slc6a1–/– mice. Journal of Clinical Investigation. https://doi.org/10.1172/jci182235

Vancouver

Guo W, Rioux M, Shaffo F, Hu Y, Yu Z, Xing C, et al. AAV9/SLC6A1 gene therapy rescues abnormal EEG patterns and cognitive behavioral deficiencies in Slc6a1–/– mice. Journal of Clinical Investigation. 2025. doi:10.1172/jci182235

BibTeX
@article{Guo2025,
  author = {Guo, Weirui and Rioux, Matthew and Shaffo, Frances and Hu, Yuhui and Yu, Ze and Xing, Chao and Gray, Steven J},
  title = {AAV9/SLC6A1 gene therapy rescues abnormal EEG patterns and cognitive behavioral deficiencies in Slc6a1–/– mice},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci182235}
}
Kostenlos starten →